Compare VIPS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIPS | PCVX |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.0B |
| IPO Year | 2012 | 2020 |
| Metric | VIPS | PCVX |
|---|---|---|
| Price | $13.28 | $50.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $19.58 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 2.7M | 1.4M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.79 | N/A |
| Revenue Next Year | $2.05 | N/A |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.44 | $29.10 |
| 52 Week High | $21.08 | $65.00 |
| Indicator | VIPS | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 35.04 | 51.24 |
| Support Level | N/A | $48.49 |
| Resistance Level | $15.11 | $52.00 |
| Average True Range (ATR) | 0.37 | 1.96 |
| MACD | -0.03 | 0.58 |
| Stochastic Oscillator | 0.88 | 76.02 |
Vipshop is a leading Chinese online discount retailer offering branded products at attractive discounts of 10%-90% off their original price through daily flash sales. It operates warehousing, retailing, product procurement, software development, and information technology support in-house while outsourcing to third-party logistics providers for distribution and shipments. Branded products on Vipshop's platform are sourced mostly through a consignment model with global brand partners. As of March 31, 2025, Eric Ya Shen, chair and CEO, had 64.5% voting rights. Leading Chinese social media firm and strategic shareholder Tencent also holds a 12.5% interest.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.